Michigan
48109, United States
Available to mentor
Dr. Scott’s research focuses on defining relationships between the structures and functional capacities of cytochrome P450 enzymes involved in human drug metabolism or which are drug targets. Her laboratory is best known for structures of human membrane P450 enzymes metabolizing xenobiotics (CYP1A1, CYP2A6, CYP2A13, CYP2E1) and sterols (CYP17A1, CYP11B1, CYP11B2, CYP8B1, CYP3A7), most of which were the first available. Study of xenobiotic-metabolizing P450 enzymes illuminate how drugs and procarcinogens are oxidized by individual P450 enzymes in regio- and stereospecific ways. For P450 enzymes in endogenous biological pathways, Scott lab structures provide guides to the development of inhibitors in disease pathways including prostate cancer, type 2 diabetes, and non-alcoholic fatty liver disease. Additional areas of contribution include P450/protein interactions and dynamics employing solution NMR. Overall, this work enables an understanding of human metabolism to guide the usage of drugs already developed and the design of new pharmaceutical agents.
Scott Lab Website
-
Postdoctoral FellowUniversity of Texas Medical Branch, Pharmacology and Toxicology
-
Ph.D.Rice University, Houston, TX
-
Center MemberRogel Cancer Center
-
Richard AM, Wong NR, Harris K, Sundar R, Scott EE, Pochapsky TC. Commun Chem, 2023 Sep 2; 6 (1): 183Journal ArticleSelective steroidogenic cytochrome P450 haem iron ligation by steroid-derived isonitriles.
DOI:10.1038/s42004-023-00994-3 PMID: 37660137 -
Liu J, Kandel SE, Lampe JN, Scott EE. J Biol Chem, 2023 Oct; 299 (10): 105283Journal ArticleCorrection: Human cytochrome P450 3A7 binding four copies of its native substrate dehydroepiandrosterone 3-sulfate.
DOI:10.1016/j.jbc.2023.105283 PMID: 37783037 -
Burris-Hiday SD, Scott EE. J Biol Chem, 2023 Sep; 299 (9): 105112Journal ArticleAllosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain.
DOI:10.1016/j.jbc.2023.105112 PMID: 37517692 -
Liu J, Kandel SE, Lampe JN, Scott EE. J Biol Chem, 2023 Aug; 299 (8): 104993Journal ArticleHuman cytochrome P450 3A7 binding four copies of its native substrate dehydroepiandrosterone 3-sulfate.
DOI:10.1016/j.jbc.2023.104993 PMID: 37392852 -
Burris-Hiday S, Chai M, Gross ML, Scott E. Journal of Pharmacology and Experimental Therapeutics, 2023 Jun; 385 (S3): 586Proceeding / Abstract / PosterHuman Cytochrome P450 Interactions with Redox Partner Cytochrome P450 Reductase
DOI:10.1124/jpet.122.267650 -
Liu J, Offei SD, Yoshimoto FK, Scott EE. J Biol Chem, 2023 Apr; 299 (4): 103032Journal ArticlePyridine-containing substrate analogs are restricted from accessing the human cytochrome P450 8B1 active site by tryptophan 281.
DOI:10.1016/j.jbc.2023.103032 PMID: 36806682 -
Petrunak EM, Bart AG, Peng H-M, Auchus RJ, Scott EE. J Biol Chem, 2023 Mar; 299 (3): 102999Journal ArticleHuman cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
DOI:10.1016/j.jbc.2023.102999 PMID: 36773804 -
Roberts AG, Stevens JC, Szklarz GD, Scott EE, Kumar S, Shah MB, Halpert JR. Drug Metab Dispos, 2023 Jan; 51 (1): 111 - 122.Journal ArticleFour Decades of Cytochrome P450 2B Research: From Protein Adducts to Protein Structures and Beyond.
DOI:10.1124/dmd.122.001109 PMID: 36310033